Tumor location does not influence the preferential release of these sEV subpopulations; the percentages of CD63/81+ and CD9/63/81+ sEVs demonstrated a significant increase post-brachytherapy in both anterior and posterior tumors (12 anterior vs. 7 posterior pairs). Here, CD9 is linked to neoplasm.